Partnerships
Participation in the Perkins Partners Program enhances opportunities for collaborative research, clinical trials and the acceleration of novel therapies into routine patient care. GenesisCare further strengthened its role in the rapidly evolving field of Theranostics through collaboration with the National Imaging Facility (NIF) at the Harry Perkins Institute , supporting advanced imaging and Theranostics focused clinical trials. In addition, GenesisCare partnered with industry collaborators Cyclowest and Quantam to support Theranostics studies that leverage specialised radiopharmaceutical manufacturing and radio-labelling capabilities. Together, these collaborations position GenesisCare at the forefront of precision oncology and reinforce its commitment to research-driven, patient-centred care. In parallel, GenesisCare continued to invest in research capacity building and workforce development. In partnership with UNSW , GenesisCare is supporting a physics PhD student over a three-year program. The student’s research focuses on the application of deep learning techniques using largescale
In 2025, GenesisCare continued to build on its strong foundation of strategic partnerships, recognising collaboration as a critical driver of research excellence and innovation in cancer care. Through sustained engagement with leading Australian universities, including the University of Sydney, the University of New South Wales (UNSW) and Edith Cowan University, as well as local health districts and research organisations , GenesisCare actively contributed to and collaborated on a growing portfolio of externally led research projects. These partnerships strengthen translational research and support the rapid integration of evidence-based advances into clinical practice. A key milestone during the year was GenesisCare’s inclusion in the Perkins Partners Program at the Harry Perkins Institute of Medical Research. This partnership aims to bring together cutting- edge research and worldclass specialised healthcare, closely aligning with GenesisCare’s established leadership in radiation therapy and its expanding footprint in medical oncology, theranostics and personalised medicine.
clinical data, combining GenesisCare datasets with broader data from the Australian Clinical Cancer Data Network . This collaboration exemplifies GenesisCare’s commitment to advancing data-driven innovation in oncology and fostering the next generation of clinician-scientists and researchers. GenesisCare continues to work closely with Cancer Australia to embed and strengthen our existing partnership to implement the Australian Cancer Plan, building on a shared commitment to improving cancer outcomes through collaboration, evidence-based policy, and system-wide impact. Through ongoing engagement under the Partnership Agreement, GenesisCare is supporting national efforts to advance cancer control priorities, contribute clinical expertise and insights from service delivery, and help translate research and policy into meaningful improvements for patients. This work reflects a mutual focus on strengthening coordination across the cancer ecosystem and ensuring that innovation, access, and quality remain central to Australia’s cancer response.
Moving forward into 2026, we are formalising partnerships with both Omico and Rare Cancers Australia (RCA) . Both GenesisCare and Omico share a commitment to expanding access to precision oncology and improving outcomes for patients with complex and advanced cancers. The proposed collaboration will increase referrals to Omico for comprehensive genomic profiling and treatment matching for patients with incurable cancer, strengthen the use of data to inform treatment and follow-up, and improve access to and coordination of clinical trials across geographies. These efforts will also support precision oncology becoming standard of care. The proposed partnership with RCA will reflect a shared commitment to improving outcomes and access to specialised support for people diagnosed with rare and less common cancers which affect around one in four Australians diagnosed with cancer and account for more than a third of cancer-related deaths nationally. Through this collaboration, GenesisCare and RCA will work together to enhance patient access to information, expertise and therapies.
Pictured left to right: Exercise oncology researcher: Mary Kennedy, Clinical Director Theranostics: A/Prof Joe Cardaci, Radiation Oncologist, Medical Director GenesisCare WA: A/Prof Yvonne Zissiadis, Prof Peter Leedman AO, Perkins Corporate Engagement Partner: Celia Byatt, Radiation Oncologist: A/Prof Raphael Chee, Nuclear Medicine and Theranostics Lead: Tiffany Briggs
Rare Cancers Australia Canforum25 (L-R: CEO, GenesisCare Australia: Richard Lizzio, CEO, RCA: Christine Cockburn, Head of Government Affairs: Natalie Cope, Head of Partnerships, RCA: Nikki Kerr)
28
29
Made with FlippingBook Annual report maker